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Abstract
Background Millennium Development Goal (MDG) 6 focused on halting the spread of HIV/AIDS. Since this goal was 
established, more development assistance for health has been devoted to combat HIV/AIDS in low-income and 
middle-income countries than any other cause of illness. In this study, we aim to track development assistance for the 
prevention and treatment of HIV/AIDS at a granular level, assessing the priorities over time for each major donor.
Methods We extracted data from the Institute for Health Metrics and Evaluation’s Financing Global Health 2015 report. 
This report systematically tracks development assistance for health care from 1990 to 2015, and splits this assistance 
into more than 20 health focus areas, drawing data from all the main international development agencies working 
with HIV/AIDS, including all bilateral aid agencies and the US President’s Emergency Plan for AIDS Relief; the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria; the World Bank; the Gates Foundation, and the Joint United 
Nations Programme on HIV/AIDS. We used budget documents and project descriptions to track donors’ priorities 
and to categorise investments. We report the sources of the funds, primary channels of delivery, and the recipient 
countries. 
Findings Since 2000, US$100·4 billion of development assistance has been provided for HIV/AIDS. In 2014, 
$10·9 billion was disbursed. Between 2000 and 2010, assistance for HIV/AIDS grew at an annualised rate of 23%. 
However, since 2010, the annualised rate of growth has been less than 1%. The US Government was the largest 
source of development assistance for HIV/AIDS during the MDG era, between 2000 and 2015, providing 56% of all 
funding. The US Government prioritised treatment (40% of its fund in 2014) and prevention (31%), whereas the 
Global Fund to Fight AIDS, Tuberculosis, and Malaria splits its investments between prevention, strengthening of 
health systems, and treatment. UNAIDS focused more than 60% of its assistance on the strengthening of health 
systems. Across all recipient countries, an average of $3600 per HIV/AIDS disability-adjusted life-year was disbursed 
between 2000 and 2014. 
Interpretation The scale-up of development assistance for HIV/AIDS has been both remarkable and diverse, with 
diﬀ erent agencies prioritising diﬀ erent investment strategies. Understanding spending patterns and comparative 
advantages provides insight into what agencies can contribute as the global AIDS community transitions from the 
MDGs to the Sustainable Development Goals.
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